Enterprise Value
64.4M
Cash
16.21M
Avg Qtr Burn
-24.85M
Short % of Float
16.95%
Insider Ownership
22.98%
Institutional Own.
36.09%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ENTADFI™ (tadalafil and finasteride) Details Benign prostatic hyperplasia (BPH) | Approved Update | |
Enobosarm +/- abemaciclib Details HER2-expressing cancers, ER+/HER2- breast cancer | Phase 3 Data readout | |
Sabizabulin (Veru-111) Details COVID-19 | Phase 3 Initiation | |
Sabizabulin (VERU-111) + Enobosarm Details Triple-negative breast cancer , Cancer | Failed Discontinued | |
VERU-100 Details Prostate cancer, Cancer | Failed Discontinued | |
Zuclomiphene citrate Details Hot flashes | Failed Discontinued | |
Sabizabulin (VERU-111) Details Castration-resistant prostate cancer | Failed Discontinued |